BNET Industries
Novartis AG is in the Pharma Industry
Latest News and Analysis
Big Pharma Pipeline: Why So Dry?
Saj Karsan submits: Pharmaceutical companies are trading well below their historical P/E levels. To anyone who follows the industry, this comes as no surprise. After a slew of blockbuster drugs that hit the market several years ago, the R&D departments of the largest companies have been coming up empty as...
Novartis Takes $235 Million Charge After Stopping Trial
ZURICH (Reuters) - Novartis AG NOVN stopped development of its Aurograb treatment for bacterial infections after it showed a lack of efficacy in mid-stage trials, and said it would take a $235 million impairment charge. The Swiss drugmaker said on Friday the charge,...
NICE Endorses Novartis Eye Drug Lucentis
LONDON (Reuters UK) - The healthcare cost-effectiveness watchdog NICE has recommended Novartis's pricey eye drug Lucentis, under a special scheme that will cap the cost of treatment to the state health service. The move, which follows a draft plan agreed last December, means the National...
Largest Companies in the World
Hickey and Walters Bespoke submit: Below we highlight the 30 largest companies in the World by market cap ($). As shown, Exxon Mobil XOM is the top dog by about $70 billion. Exxon is trailed by another energy company, Petrochina PTR, then General Electric GE and Microsoft MSFT. ...
Time to Invest in Pharmaceuticals?
Howard Sun submits: The prices of many pharmaceutical companies have been beaten down by Wall Street in recent months. With companies like Pfizer PFE, Schering-Plough SGP and Bristol-Myers Squibb BMY reaching lower lows, one has to wonder when the pain will end as these companies are now significantly undervalued. The...
Companies With Recent, Innovative Product Approvals vs. Healthcare ETFs
Mike Havrilla submits: The table below presents a global index of healthcare companies that have received FDA approval for innovative products in the last 12 months. The index excludes all approvals for label expansions of existing products and reformulations of existing products to select only original product approvals -- including...
Novartis Example: Why Drug Discovery / Development Is Hard
Eben Tessari submits: FTY270 fingolimod, an S1P1 modulator, is a T-cell specific immunosuppressant and is a hot, emerging phase III therapy for MS from Novartis NVS. So where is the difficulty? In the Aug. 14, 2008, issue of Nature, scientists from Emory University and the Yerkes Primate Research...
Big Pharma?s Healthy Appetite for Acquisitions
Santosh Sankar submits: Healthcare, more specifically Pharma is showing an appetite for deal making as four major companies are courting potential acquisitions. This hunger signals a change in the environment as signs of consolidation surface. If we look at this year’s activity, IPOs were at an all time low and...
Like a Fine Watch, a Swiss Fund
George Spritzer submits: I recently purchased a longer term position in the Swiss Helvetia Fund SWZ. SWZ is a non-diversified, closed-end fund that invests in equity and equity-linked securities of Swiss companies. Here are some reasons I like SWZ:1) Discount to NAV yesterday was 12.9%. The annual expense ratio...
New Analyst Reports for GOLDSOURCE MINES INC, PURE ENERGY SERVICES LTD, NOVARTIS AG, and CITIZENS COMMUNICATIONS CO
MaybachFinancial.com is one of the fastest growing independent and unbiased research firms in the world. Through our numerous partnerships with many of the top investment minds in the world, we provide research on companies making a move in the markets. Investors seeking genuine analyst opinions on their investments for GOLDSOURCE...
Novartis, Pfizer and Merck Take the Lead on Strong Relationships with Physicians, as Doctors Demand an Expanding Set of Services
NEW YORK, June 17 /PRNewswire/ -- Among US primary care physicians, Novartis earns the highest sales rep relationship scores, followed by Pfizer, Merck, GlaxoSmithKline and Sanofi-Aventis, according to new research from TNS Healthcare. Novartis also takes the top spot in Europe, demonstrating a consistent ability to build strong...
Protez Pharmaceuticals to Be Acquired by Novartis
Acquisition positions Protez to advance promising development program for hospital antibiotics, including PZ-601, a uniquely broad-spectrum antibiotic in Phase II development to help patients suffering from life-threatening infections
Antisoma receives USD 25 million milestone payment from Novartis
London, UK, 29 May 2008 - Antisoma (LSE: ASM; USOTC:ATSMY) announces that it has received a milestone payment of USD 25 million from Novartis. This was triggered by the recent initiation of a phase III trial of ASA404 in non-small cell lung cancer.
Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
- Unprecedented amount of research reflects depth and breadth of collaboration with investigators worldwide to develop new treatments for diverse forms of cancer
In a Phase II Study, Novartis Meningitis B Vaccine Has Potential to Produce a Protective Immune Response in Infants, the Age Group Most at Risk
-- Data show Novartis Meningitis B MenB vaccine has potential to be first vaccine to provide broad protection to infants against meningococcal B infections -- The meningococcal B strain causes 72% of meningococcal disease in ...
Novartis Menveo(R) Vaccine Shows Superior Immune Response Against Four Types of Meningitis Disease in Pivotal Phase III Trial
New Phase III data for Menveo® (MenACWY-CRM) show that the vaccine produced a greater immune response against meningococcal serogroups A, C, W-135 and Y in adolescents 11-18 years of age compared to Menactra®. Infection with any of these four vaccine-preventable serogroups can lead to bacterial meningitis, an infection of the...
Novartis names new US leaders amid streamlining
NOVARTIS NAMED Ludwig Hantson to head its US pharmaceuticals business.
Novartis reports higher sales and earnings in first quarter of 2008 showing healthcare portfolio well on the way to new growth cycle
* Novartis on track in 2008:
Novartis to further strengthen its healthcare portfolio by acquiring 25% stake in Alcon from Nestlé with right to take over majority ownership of the world leader in eye care
Definitive agreement with Nestlé S.A. provides Novartis the right to acquire 77% majority ownership of Alcon in two steps
Endo, Novartis begin agreement
ENDO Pharmaceuticals has entered into a licensing agreement with Novartis to obtain the exclusive US marketing rights for Voltaren Gel diclofenac sodium topical gel 1%. Endo said it expects to commercialize Voltaren Gel using one of its two specialty sales forces, consisting of 160 reps, prior to executing a full...
- Next »
- page 1 of 42
- « Previous
Sort byClose
View by Content TypeClose
View Related Content by Tag Close
- Health Care (40 results)
- sales (38 results)
- Pharmaceutical Company (33 results)
- FDA (24 results)
- Pfizer Inc. (24 results)
- agreement (22 results)
- Merger (20 results)
- Chiron Corp. (19 results)
- marketing (17 results)
- advertisement (16 results)
- Patient (15 results)
- Merck & Co. Inc. (14 results)
- vaccine (13 results)
- AstraZeneca Plc. (13 results)
- food (13 results)
- Hackensack (13 results)
- nutrition (12 results)
- Roche Holding AG (12 results)
- biotechnology (12 results)
- brand (12 results)
- collaboration (11 results)
- Industry (10 results)
- Aventis (9 results)
- R&D (9 results)
- life science (9 results)
- GlaxoSmithKline Plc. (9 results)
- Sandoz (8 results)
- Schering-Plough Corp. (8 results)
- Bristol-Myers Squibb Co. (8 results)
- acquisition (8 results)
- Nestlé (7 results)
- Sanofi-Aventis (7 results)
- blog (7 results)
- Investment (6 results)
- therapy (6 results)
- agency (6 results)
- Genentech Inc. (6 results)
- Finance (6 results)
- Strategy (6 results)
- Healthcare (6 results)
- Siebel Systems Inc. (5 results)
- U.S. Environmental Protection Agency (5 results)
- shareholder (5 results)
- Manufacturing (5 results)
- board (5 results)
- company (5 results)
- stock (5 results)
- benefit (5 results)
- New York Stock Exchange (4 results)
- Credit Suisse First Boston (4 results)
Novartis AG Company Info
NAICS Code
Pharmaceutical Preparation Manufacturing: 325412
